)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SenzaGen
SenzaGen (SENZA) investor relations material
SenzaGen BioStock Life Science Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.BioStock Life Science Summit 2026 summary5 Nov, 2026
Market and portfolio
Non-animal testing market estimated at $13B, with a $0.6B serviceable market and projected 6%–10% growth; demand driven by cost, sustainability, scientific progress and regulation.
Four complementary businesses offer GARD toxicology testing, VitroScreen’s ORA efficacy platform, ToxHub regulatory advisory and Alcyomics’ immunotoxicology services.
Platforms include GARD for sensitization, ORA for efficacy testing and Skimune for human ex vivo immunotoxicology, with particular strength in biologics.
Alcyomics acquisition
Acquisition adds a profitable, high-growth U.K. business, expands into pharma and biologics, and supports the growth plan and path to long-term profitability.
FDA welcomes non-animal-testing submissions for IND files; management sees no barrier to transition, as technology and data are available.
Q3 performance
Q3 top line grew 9% currency-adjusted; GARD grew 7%; gross margin was 77%, supported by increased licensing income; operating costs stayed at the prior-year level.
First positive quarterly EBIT was SEK 1.1M; EBITDA was positive for 9M. Results preceded the Alcyomics acquisition, which was signed during the week.
Added 12 new customers in Q3, mainly in chemicals, alongside repeat business from larger customers.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SenzaGen
- First quarterly EBIT profit and Alcyomics deal broaden growth opportunities.SENZA
Q3 2026 - Alcyomics expands non-animal biologics testing and supports growth toward 2030.SENZAM&A announcement
- Q2 2026 revenue up 13%, margins improved, and positive cash flow supports growth outlook.SENZAQ2 2026
- 10% revenue growth, robust GARD® sales, and a stronger financial position after share issue.SENZAQ1 2026
- Record GARD® sales, strong order book, and new investment set the stage for 2026 growth.SENZAQ4 2025
- Q3 2025 delivered 15% revenue growth and break-even EBITDA, with strong GARD® and ToxHub sales.SENZAQ3 2025
- Expanded OECD approval and strong order intake set the stage for H2 2025 growth.SENZAQ2 2025
- GARD-skin's expanded OECD TG 497 approval boosts predictive power and market potential.SENZAStatus Update
- Gross margin 75%, cash SEK 34.7M, and regulatory wins set up H2 2025 growth.SENZAQ1 2025
Next SenzaGen earnings date
Q4 202618 Feb, 2027
SenzaGen
Next SenzaGen earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SenzaGen is a Sweden-based biotechnology company specializing in non-animal test methods for assessing chemical safety. The company develops and markets in vitro assays for detecting skin sensitization and other toxicological endpoints. Its technology is used in industries including cosmetics, chemicals, and pharmaceuticals. SenzaGen is headquartered in Lund, Sweden, and its shares are listed on the NASDAQ First North Growth Market.